FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280491532> ?p ?o ?g. }

• W4280491532 endingPage "618" @default.
• W4280491532 startingPage "618" @default.
• W4280491532 abstract "As COVID-19 continues to pose major risk for vulnerable populations, including the elderly, immunocompromised, patients with cancer, and those with contraindications to vaccination, novel treatment strategies are urgently needed. SARS-CoV-2 infects target cells via RGD-binding integrins, either independently or as a co-receptor with surface receptor angiotensin-converting enzyme 2 (ACE2). We used pan-integrin inhibitor GLPG-0187 to demonstrate the blockade of SARS-CoV-2 pseudovirus infection of target cells. Omicron pseudovirus infected normal human small airway epithelial (HSAE) cells significantly less than D614G or Delta variant pseudovirus, and GLPG-0187 effectively blocked SARS-CoV-2 pseudovirus infection in a dose-dependent manner across multiple viral variants. GLPG-0187 inhibited Omicron and Delta pseudovirus infection of HSAE cells more significantly than other variants. Pre-treatment of HSAE cells with MEK inhibitor (MEKi) VS-6766 enhanced the inhibition of pseudovirus infection by GLPG-0187. Because integrins activate transforming growth factor beta (TGF-β) signaling, we compared the plasma levels of active and total TGF-β in COVID-19+ patients. The plasma TGF-β1 levels correlated with age, race, and number of medications upon presentation with COVID-19, but not with sex. Total plasma TGF-β1 levels correlated with activated TGF-β1 levels. Moreover, the inhibition of integrin signaling prevents SARS-CoV-2 Delta and Omicron pseudovirus infectivity, and it may mitigate COVID-19 severity through decreased TGF-β1 activation. This therapeutic strategy may be further explored through clinical testing in vulnerable and unvaccinated populations." @default.
• W4280491532 created "2022-05-22" @default.
• W4280491532 creator A5010292765 @default.
• W4280491532 creator A5015302057 @default.
• W4280491532 creator A5029992402 @default.
• W4280491532 creator A5032855671 @default.
• W4280491532 creator A5068051991 @default.
• W4280491532 creator A5075201353 @default.
• W4280491532 date "2022-05-17" @default.
• W4280491532 modified "2023-10-18" @default.
• W4280491532 title "Integrin/TGF-β1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity" @default.
• W4280491532 cites W1237762235 @default.
• W4280491532 cites W1576773659 @default.
• W4280491532 cites W1973474133 @default.
• W4280491532 cites W1982533785 @default.
• W4280491532 cites W2005165360 @default.
• W4280491532 cites W2013381560 @default.
• W4280491532 cites W2119494556 @default.
• W4280491532 cites W2125061065 @default.
• W4280491532 cites W2135846773 @default.
• W4280491532 cites W2140256258 @default.
• W4280491532 cites W2314729200 @default.
• W4280491532 cites W2342679639 @default.
• W4280491532 cites W2574998181 @default.
• W4280491532 cites W2603381469 @default.
• W4280491532 cites W2766262082 @default.
• W4280491532 cites W3008876765 @default.
• W4280491532 cites W3022435472 @default.
• W4280491532 cites W3022602407 @default.
• W4280491532 cites W3025847192 @default.
• W4280491532 cites W3038109355 @default.
• W4280491532 cites W3041140240 @default.
• W4280491532 cites W3042744336 @default.
• W4280491532 cites W3046930850 @default.
• W4280491532 cites W3093454821 @default.
• W4280491532 cites W3103795481 @default.
• W4280491532 cites W3114778087 @default.
• W4280491532 cites W3119344443 @default.
• W4280491532 cites W3120815116 @default.
• W4280491532 cites W3121578947 @default.
• W4280491532 cites W3130076812 @default.
• W4280491532 cites W3137680416 @default.
• W4280491532 cites W3142457473 @default.
• W4280491532 cites W3172207918 @default.
• W4280491532 cites W3176719069 @default.
• W4280491532 cites W3184202385 @default.
• W4280491532 cites W3185650777 @default.
• W4280491532 cites W3191468861 @default.
• W4280491532 cites W3198065839 @default.
• W4280491532 cites W3202256154 @default.
• W4280491532 cites W3205159792 @default.
• W4280491532 cites W3210386674 @default.
• W4280491532 cites W3211150081 @default.
• W4280491532 cites W4200186202 @default.
• W4280491532 cites W4200247221 @default.
• W4280491532 cites W4200391585 @default.
• W4280491532 cites W4200487801 @default.
• W4280491532 cites W4200549894 @default.
• W4280491532 cites W4205954186 @default.
• W4280491532 cites W4206109384 @default.
• W4280491532 cites W4206135665 @default.
• W4280491532 cites W4225982774 @default.
• W4280491532 cites W4226192094 @default.
• W4280491532 cites W60647485 @default.
• W4280491532 doi "https://doi.org/10.3390/ph15050618" @default.
• W4280491532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35631444" @default.
• W4280491532 hasPublicationYear "2022" @default.
• W4280491532 type Work @default.
• W4280491532 citedByCount "12" @default.
• W4280491532 countsByYear W42804915322022 @default.
• W4280491532 countsByYear W42804915322023 @default.
• W4280491532 crossrefType "journal-article" @default.
• W4280491532 hasAuthorship W4280491532A5010292765 @default.
• W4280491532 hasAuthorship W4280491532A5015302057 @default.
• W4280491532 hasAuthorship W4280491532A5029992402 @default.
• W4280491532 hasAuthorship W4280491532A5032855671 @default.
• W4280491532 hasAuthorship W4280491532A5068051991 @default.
• W4280491532 hasAuthorship W4280491532A5075201353 @default.
• W4280491532 hasBestOaLocation W42804915321 @default.
• W4280491532 hasConcept C118131993 @default.
• W4280491532 hasConcept C126322002 @default.
• W4280491532 hasConcept C159047783 @default.
• W4280491532 hasConcept C170493617 @default.
• W4280491532 hasConcept C195687474 @default.
• W4280491532 hasConcept C203014093 @default.
• W4280491532 hasConcept C71924100 @default.
• W4280491532 hasConcept C86803240 @default.
• W4280491532 hasConcept C95444343 @default.
• W4280491532 hasConceptScore W4280491532C118131993 @default.
• W4280491532 hasConceptScore W4280491532C126322002 @default.
• W4280491532 hasConceptScore W4280491532C159047783 @default.
• W4280491532 hasConceptScore W4280491532C170493617 @default.
• W4280491532 hasConceptScore W4280491532C195687474 @default.
• W4280491532 hasConceptScore W4280491532C203014093 @default.
• W4280491532 hasConceptScore W4280491532C71924100 @default.
• W4280491532 hasConceptScore W4280491532C86803240 @default.
• W4280491532 hasConceptScore W4280491532C95444343 @default.
• W4280491532 hasFunder F4320309070 @default.

• next